Tissue and transplant logistics moves human allografts, bone, skin, cornea, and heart valve grafts recovered from a deceased or living donor, from a tissue bank or recovery site to the operating room where a surgeon implants them. Unlike an organ, which must be transplanted within hours, most tissue grafts are processed and either cryopreserved or freeze-dried after recovery, which turns the shipment into a scheduled logistics problem instead of an emergency one. That single difference, tissue can wait, an organ cannot, is what separates this chain from organ transport and lets it run on standard carrier networks instead of dedicated medical flights.
A hospital tissue bank holds an inventory of processed grafts the way a blood bank holds blood products, shipping units out against surgical schedules booked weeks or months ahead. That inventory model is only possible because processing and preservation extend a graft's usable life far beyond what a fresh, unprocessed tissue would tolerate.
Cryopreservation versus hypothermic storage
Bone and heart valve grafts are usually cryopreserved, frozen deep enough, often below -80°C in a mechanical freezer or in vapor-phase nitrogen, that cellular activity stops almost entirely and the graft can be stored for years before use. See cryogenic shipping for how that cold is held once the graft leaves the bank. Skin grafts split down two paths: some are cryopreserved to keep the living cell layer viable, others are glycerol-preserved instead, a process that trades living cells for a graft that tolerates ordinary refrigeration and a much longer shelf life.
Cornea tissue takes a different route. A cornea is thin enough that deep freezing damages its cell layer, so it is stored hypothermically instead, chilled to a 2-8°C refrigerated band in a preservation medium, and used within one to two weeks of recovery. That short window means cornea logistics runs closer to a perishable product than a banked one: eye banks match a recovered cornea to a scheduled recipient and ship it out almost immediately, rather than holding it in long-term inventory.
Distribution through regional tissue banks
Recovered tissue moves first to a processing center, where it is disinfected, shaped, and preserved, then to a tissue bank that holds finished inventory, and finally to the hospital that ordered it for a scheduled procedure. Most domestic shipments move by ground or scheduled air courier because the transit window, even for a hypothermic cornea, is measured in days rather than hours. International tissue trade exists for grafts in short domestic supply, though it adds import screening and customs handling on top of the preservation logistics already involved.
Demand for a specific graft size or type can sit unmet for months if the matching donor tissue has not been recovered recently, since supply depends entirely on donation rates rather than a manufacturer's production schedule. A surgeon booking a procedure around a particular graft size sometimes has to wait on inventory the same way a transplant center waits on a matched organ, just on a slower, less urgent clock.
Donor traceability and chain of custody
Every graft that ships carries a lot number tracing back to a single donor, and that link cannot break at any point in the chain. A processing center, a tissue bank, and a hospital each log the graft's chain of custody independently, because a disease transmitted through a graft has to be traceable back to the donor and forward to every recipient who received tissue from the same recovery, not just the one patient in front of the surgeon. This traceability requirement is why tissue shipments carry more paperwork per unit than most other cold chain cargo, even though the physical package is often just a small vial or a rigid container.
Limits of the hypothermic window
Hypothermic storage only works for tissue that tolerates a short shelf life measured in days, which rules it out for any graft a bank wants to hold as standing inventory. A cornea cannot be banked the way a cryopreserved bone graft can, so eye banks operate on a match-and-ship model tied to actual surgical bookings rather than stocking ahead of demand. Reaching for cryopreservation to extend that window is not free either: freezing damages some cell types that validated processing steps cannot fully protect, which is why the industry runs hypothermic and cryopreserved paths side by side for different tissue types rather than treating cryopreservation as a universal upgrade.
Standards bodies and the people who run this chain
Organ procurement organizations and tissue banks recover and process the graft, accredited processors prepare and preserve it, and hospital surgical teams schedule its use against a specific patient. Regulators treat human tissue as a distinct category from a manufactured drug, requiring donor screening and infectious disease testing rather than the batch release testing a pharmaceutical undergoes, though the biologics cold chain shares some of the same refrigerated and cryogenic packaging once a tissue product leaves the bank. Blood banks run a parallel traceability model for donated blood products, and the two systems, blood cold chain and tissue banking, often share the same regional infrastructure and staff.